---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-065623"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2023-11-22T23:59:59+00:00"
generated_at: "2026-06-07T22:21:17.682058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q3 net loss $7.4M; FDA Approvable Letter for pediatric AKI device received

## Summary
- Net loss $7.4M ($0.37/share) vs $1.9M ($0.26/share) YoY; no revenue as pre-commercial stage.
- Cash $73,000 at Sep 30, raised $3.5M convertible notes in Aug-Sep 2023.
- Received FDA Approvable Letter for SCD-PED; formal approval expected Dec 2023-Jan 2024.
- Breakthrough Device Designation granted for cardiorenal and hepatorenal syndromes in Sep-Oct 2023.
- NEUTRALIZE-AKI adult trial enrolled 7 patients; target 200 at up to 30 U.S. sites.

## SEC filing metadata
- accession: 0000950170-23-065623
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2023-11-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/0000950170-23-065623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/icu-20231121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-065623
- JSON: https://secwatch.observer/filing/0000950170-23-065623.json
- Plain text: https://secwatch.observer/filing/0000950170-23-065623.txt

## Key facts
- Earnings Releases
  SeaStar Medical Holding Corp reported financial results for three and nine months ended September 30, 2023.
  - Period: three and nine months ended September 30, 2023
  - Result: reported results
  source text: reports financial results for the three and nine months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/0000950170-23-065623-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.